Related Experiment Videos
Selective aromatase inhibition for patients with androgen-independent prostate carcinoma
Matthew R Smith1, Donald Kaufman, Daniel George
1Department of Hematology Oncology, Massachusetts General Hospital, Boston 02114, USA. smith.matthew@mgh.harvard.edu
Background:
First and second-generation aromatase inhibitors have shown activity in patients with androgen-independent prostate carcinoma. These early-generation aromatase inhibitors are nonselective, however, and inhibition of other steroidogenic enzymes may contribute to their reported clinical activity. The authors conducted a Phase II clinical study of letrozole to determine the safety and efficacy of a potent and selective third-generation aromatase inhibitor in men with androgen-independent prostate carcinoma.
Methods:
Forty-three men with androgen-independent prostate carcinoma were treated with oral letrozole (2.5 mg daily). Treatment was continued until progressive disease or Grade 3 toxicity developed. Response and progressive disease were defined according to recommendations of the Prostate Specific Antigen Working Group.
Results:
In total, 380 weeks of treatment were administered to the 43 study patients. The median duration of treatment was 8 weeks. Forty men discontinued treatment due to progressive disease. Only one patient responded to treatment with a sustained decrease > 50% in serum prostate specific antigen (PSA) levels. Three other patients experienced transient minor decreases (< 50%) in serum PSA levels. There were no serious treatment-related adverse events.
Conclusions:
Selective aromatase inhibition with letrozole is not active in men with androgen-independent prostate carcinoma.
Insights
Letrozole, a selective aromatase inhibitor, showed no significant efficacy in treating men with androgen-independent prostate cancer. The study found minimal prostate-specific antigen (PSA) response, indicating limited clinical activity for this treatment in advanced prostate cancer.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- First and second-generation aromatase inhibitors have demonstrated activity in androgen-independent prostate carcinoma.
- These earlier inhibitors are nonselective, potentially affecting multiple steroidogenic enzymes.
- A Phase II study evaluated letrozole, a potent and selective third-generation aromatase inhibitor, in this patient population.
Purpose of the Study:
- To determine the safety and efficacy of letrozole in men with androgen-independent prostate carcinoma.
- To assess the clinical activity of a selective third-generation aromatase inhibitor.
Main Methods:
- A Phase II clinical study involving 43 men with androgen-independent prostate carcinoma.
- Patients received oral letrozole at 2.5 mg daily until disease progression or Grade 3 toxicity.
- Response was evaluated based on Prostate Specific Antigen (PSA) Working Group recommendations.
Main Results:
- The median treatment duration was 8 weeks, with 40 patients discontinuing due to progressive disease.
- Only one patient achieved a sustained >50% decrease in serum PSA levels; three others had transient minor decreases.
- No serious treatment-related adverse events were reported.
Conclusions:
- Selective aromatase inhibition with letrozole is not effective in men with androgen-independent prostate carcinoma.
- The findings suggest limited clinical utility of letrozole for this specific cancer type and stage.